in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans. Transfusion 1999; 39(11–12):1169–1178.99 99. Kasper C, Lusher J. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion 1993; 33(5):422–434.
100 100. Aronson D. The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A. Transfusion 1990; 30(8):748–758.
101 101. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates. Am J Hematol 1992; 39(3):228–230.
102 102. An outbreak of hepatitis A related to a solvent/detergent treated factor VIII concentrate (Alphanate). MMWR 1996; 45:29–32.
103 103. Lusher JM, Arkin S, Abilgaard CF, Schwartz RS. Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A. Surv Anesthesiol 1993; 37(5):307.
104 104. Bray G, Gomperts E, Courter S. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83:2428–2437.
105 105. Kasper CK. Plasma‐derived versus recombinant factor VIII for the treatment of hemophilia A. Vox Sang 1996; 70(S3):17–20.
106 106. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62(10):1614–1622.
107 107. Mannucci PM, Bauer KA, Gringeri A, et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76:2540–2545.
108 108. Fenger‐Eriksen C, Lindberg‐Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101(6):769–773.
109 109. Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res 2009; 124(Suppl 2):S9–S11.
110 110. Rahe‐Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high‐normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102(6):785–792.
111 111. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125(9):1387–1393.
112 112. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ‐globulin. Vox Sang 1962; 7(2):157–174.
113 113. Knezevic‐Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10):1460–1480.
114 114. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017; 139(3):S1–S46.
115 115. Ratko TA. Recommendations for off‐label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273(23):1865.
116 116. Scaradavou A, Bussel JB. Clinical experience with anti‐D in the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 1998; 35:52–57.
117 117. Rushin J, Rumsey DH, Ewing CA, Sandler SG. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin. Transfusion 2000; 40(5):551–554.
118 118. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion. 2007; 47(12):2180–2184.
119 119. Alter HJ. Pathogen Reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22(2):97–102.
120 120. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a consensus conference: pathogen inactivation—making decisions about new technologies. Transfus Med Rev 2008; 22(1):1–34.
121 121. Prowse C. Properties of pathogen‐inactivated plasma components. Transfus Med Rev 2009; 23(2):124–133.
122 122. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013; 104(3):183–199.
123 123. Doree B, Estcourt LJ, Trivella M. Pathogen‐reduced platelets for prevention of bleeding (review). Reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration, The Cochrane Library, 3rd edn. Chichester, UK: John Wiley & Sons, Ltd., 2013.
124 124. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasma. Transfusion 2000; 40(10):1203–1206.
125 125. Flamholz R, Jeon H‐R, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent‐treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15(3):169–172.
126 126. Solheim B, Hellstern P. Composition, efficacy, and safety of S/D‐treated plasma. Transfusion 2003; 43:1176–1178.
127 127. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh‐frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007; 93(2):154–158.
128 128. Santagostino E, Mancuso M, Morfini E, et al. Solvent/detergent plasma for the prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 2006; 91(5):634–639.
129 129. Williamson LM, Cardigan R, Prowse CV. Methylene blue‐treated fresh‐frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43(9):1322–1329.
130 130. Garwood M, Cardigan RA, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh‐frozen plasma. Transfusion 2003; 43(9):1238–1247.
131 131. Hornsey VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49(10):2167–2172.
132 132. Hambleton J, Wages D, Radu‐Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42(10):1302–1307.
133 133. Mohr H, Gravemann U, Müller TH. Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light. Transfusion 2009; 49(10):2144–2151.
134 134. Mintz PD. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107(9):3753–3760.
135 135. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46(10):1693–1704.
136 136. Mohr H, Steil L, Gravemann U, et al. Blood components: a novel approach to pathogen reduction in platelet concentrates using short‐wave ultraviolet light. Transfusion 2009; 49(12):2612–2624.
137 137. Lin L,
